Evidence map›Paper›PMID 33004309›Full record

ArticleJournal of genetics and genomics = Yi chuan xue bao2020

A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.

Yicheng Chen, Yiqing Zhao, David L Bajor, Zhenghe Wang, J Eva Selfridge

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of genetics and genomics = Yi chuan xue bao, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yicheng ChenDepartment of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA; Case Comprehensive Cancer Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
Yiqing ZhaoDepartment of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA; Case Comprehensive Cancer Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
David L BajorDepartment of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA; Case Comprehensive Cancer Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA; Seidman Cancer Center, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Zhenghe WangDepartment of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA; Case Comprehensive Cancer Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA. Electronic address: zxw22@case.edu.
J Eva SelfridgeDepartment of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA; Case Comprehensive Cancer Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA; Seidman Cancer Center, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA. Electronic address: jennifer.selfridge@uhhospitals.org.
Case Western Reserve University · USUniversity Hospitals of Cleveland · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and PreventionP50CA150964 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2011 to 2022
$24.6M
TRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2M
Mechanisms of metabolic reprogramming by PIK3CA oncogenic mutationsR01CA196643 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Zhenghe Wang · 2016 to 2026
$3.1M
NRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9M
High throughput screen for GPT2 inhibitors to target PIK3CA-mutant cancersUH2CA223670 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI WANG, ZHENGHE · 2018 to 2019
$378k
NCATS NIH HHS TL1 TR002549NCI NIH HHS K12 CA076917NCI NIH HHS P30 CA043703NCI NIH HHS P50 CA150964NCI NIH HHS R01 CA196643NCI NIH HHS UH2 CA223670
6 · The paper itself

Abstract

Many cancer types reprogram their metabolism to become addicted to glutamine. One of the critical enzymes in the utilization of glutamine in these cells is glutaminase. CB-839 (telaglenastat) is a drug that targets glutaminase that is currently being evaluated in many clinical trials for efficacy in various cancer types that are known to be driven by glutamine metabolism. Despite its use, there are limited assays available for testing the pharmacodynamic on-target effects of CB-839 on the limited, small-volume patient samples that are obtained in early-phase clinical trials. Thus, we developed an assay based on the cellular thermal shift assay technique using AlphaLISA technology to show that CB-839 specifically engages glutaminase in colon cancer cell lines in vitro and in minute quantities of mouse xenograft tumors. Notably, we show that this assay detects CB-839 binding to glutaminase in platelets of patients collected while receiving CB-839 on a clinical trial. This assay may be used to study the pharmacodynamic profile of CB-839 in very small tissue samples obtained from patients on a clinical trial and may be useful in future studies designed to screen other inhibitors of glutaminase.

Indexed as

AnimalsBenzeneacetamidesCell Line, TumorColonic NeoplasmsGlutaminaseGlutamineHeterograftsHumansMiceThiadiazolesBenzeneacetamidesCB-839GlutaminaseGlutamineThiadiazolesCancerGlutaminaseMethod

Identifiers

PMID33004309
PMCPMC7704934
OpenAlexW3034369223

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.